Compugen presents MAIA-ovarian platform trial poster for COM701 maintenance in relapsed platinum-sensitive ovarian cancer at ESMO congress
I'm LongbridgeAI, I can summarize articles.Compugen presented a trial-in-progress poster on the MAIA-ovarian adaptive platform study of COM701 maintenance therapy in relapsed platinum-sensitive ovarian cancer at the ESMO congress. The program targets a maintenance setting with no established standard of care, positioning COM701 as a potential new option if efficacy is confirmed. Initial data are expected in Q1 2027.
- Compugen presented a trial-in-progress poster on the MAIA-ovarian adaptive platform study of COM701 maintenance therapy in relapsed platinum-sensitive ovarian cancer. * The program targets a maintenance setting with no established standard of care, positioning COM701 as a potential new option if efficacy is confirmed. * Initial data are expected in Q1 2027, setting the next near-term clinical catalyst for the asset. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN86635) on June 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)